Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years

Therapeutic Drug Monitoring

Volumn 34, Issue 4, 2012, Pages 381-389

  Ince, Ibrahim ^a,b   De Wildt, Saskia N ^a   Peeters, Mariska Y M ^c   Murry, Daryl J ^d   Tibboel, Dick ^a   Danhof, Meindert ^b   Knibbe, Catherijne A J ^a,b,c  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

critical illness; CYP3A4; midazolam; pediatrics; population pharmacokinetics; therapeutic drug monitoring

Indexed keywords

1 HYDROXYMIDAZOLAM; 1 HYDROXYMIDAZOLAM GLUCURONIDE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; MIDAZOLAM; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BODY WEIGHT; CHILD; CONTINUOUS INFUSION; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; INFANT; INTENSIVE CARE; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEDATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CRITICAL ILLNESS; CYTOCHROME P-450 CYP3A; GLUCURONOSYLTRANSFERASE; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS; MIDAZOLAM;

EID: 84863817212     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31825a4c3a     Document Type: Article

References (39)

1. de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485-505. (Pubitemid 30032252)
2. Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr. 1995;7:220-233.
3. Hughes J, Gill AM, Mulhearn H, et al. Steady-state plasma concentrations of midazolam in critically ill infants and children. Ann Pharmacother. 1996;30:27-30. (Pubitemid 26025415)
4. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology. 1995;104:1-8. (Pubitemid 26016371)
5. Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol. 1989;37:267-272. (Pubitemid 19242733)
6. de Wildt SN, de Hoog M, Vinks AA, et al. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med. 2003;31:1952-1958. (Pubitemid 36900749)
7. Peeters MY, Prins SA, Knibbe CA, et al. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology. 2006;105:1135-1146. (Pubitemid 44808577)
8. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35:1687-1693. (Pubitemid 47296065)
9. Carcillo JA, Doughty L, Kofos D, et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med. 2003;29:980-984. (Pubitemid 36783172)
10. de Wildt SN, Riva L, van den Anker JN, et al. Does age alter the pharmacokinetics of midazolam and l-OH-midazolam in paediatric patients? Clin Pharmacol Ther. 2000;67:104.
11. Boeckmann AJ, Beal SL, Sheiner LB. NONMEM User's Guide. California: Division of Clinical Pharmacology, University of California at San Francisco; 1998.
12. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17-20. (Pubitemid 46944205)
13. Montgomery DC, Peck EA. Introduction to Linear Regression Analysis. New York, NY: Wiley; 1982.
14. Krekels EH, van Hasselt JG, Tibboel D, et al. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res. 2011;28:797-811.
15. Ette EI, Williams PJ, Kim YH, et al. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43:610-623. (Pubitemid 36613120)
16. Brendel K, Comets E, Laffont C, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036-2049.
17. de Wildt SN, de Hoog M, Vinks AA, et al. Pharmacodynamics of midazolam in pediatric intensive care patients. Ther Drug Monit. 2005;27:98-102. (Pubitemid 40189981)
18. Bonnet F, Richard C, Glaser P, et al. Changes in hepatic flow induced by continuous positive pressure ventilation in critically ill patients. Crit Care Med. 1982;10:703-705.
19. Dahn MS, Lange P, Lobdell K, et al. Splanchnic and total body oxygen consumption differences in septic and injured patients. Surgery. 1987;101:69-80. (Pubitemid 17218381)
20. Mathews HM, Carson IW, Lyons SM, et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth. 1988;61:302-307.
21. Park GR, Miller E, Navapurkar V. What changes drug metabolism in critically ill patients? - II Serum inhibits the metabolism of midazolam in human microsomes. Anaesthesia. 1996;51:11-15.
22. Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolise midazolam. Anaesthesia. 1987;42:619-626. (Pubitemid 17118485)
23. Ding X, Staudinger JL. Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C. Biochem Pharmacol. 2005;69:867-873. (Pubitemid 40248628)
24. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 1997;29:1129-1188. (Pubitemid 28133460)
25. Craig PI, Tapner M, Farrell GC. Interferon suppresses erythromycin metabolism in rats and human subjects. Hepatology. 1993;17:230-235. (Pubitemid 23046694)
26. Haas CE, Kaufman DC, Jones CE, et al. Cytochrome P450 3A4 activity after surgical stress. Crit Care Med. 2003;31:1338-1346. (Pubitemid 36583841)
27. Kacevska M, Robertson GR, Clarke SJ, et al. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol. 2008;4:137-149. (Pubitemid 351308413)
28. Renwick AB, Watts PS, Edwards RJ, et al. Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos. 2000;28:1202-1209.
29. Yang J, Liao M, Shou M, et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab. 2008;9:384-394.
30. Kumar A, Remmel RP, Mann HJ, et al. Drug metabolism in hemorrhagic shock: pharmacokinetics of selective markers of cytochrome-P450 2C9, 2D6, and 3A4 enzyme activities in a porcine model. J Surg Res. 2011;167:231-243.
31. Kearney RA, Rosales JK, Howes WJ. Craniosynostosis: an assessment of blood loss and transfusion practices. Can J Anaesth. 1989;36:473-477. (Pubitemid 19184322)
32. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85:599-610.
33. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol. 1983;16(suppl 1):43S-49S. (Pubitemid 13006585)
34. Anderson BJ, Larsson P. A maturation model for midazolam clearance. Paediatr Anaesth. 2011;21:302-308.
35. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931-956. (Pubitemid 44299829)
36. Bjorkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet. 2006;45:1-11. (Pubitemid 43145012)
37. Knibbe CA, Krekels EH, van den Anker JN, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet. 2009;48:371-385.
38. de Gast-Bakker DA, van der Werff SD, Sibarani-Ponsen R, et al. Age is of influence on midazolam requirements in a paediatric intensive care unit. Acta Paediatr. 2007;96:414-417. (Pubitemid 46442532)
39. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet. 1994;26:292-307. (Pubitemid 24116207)